Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group.

Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15.


Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).

Nutting CM, Morden JP, Beasley M, Bhide S, Cook A, De Winton E, Emson M, Evans M, Fresco L, Gollins S, Gujral D, Harrington K, Joseph M, Lemon C, Luxon L, van den Blink Q, Mendes R, Miah A, Newbold K, Prestwich R, Robinson M, Sanghera P, Simpson J, Sivaramalingam M, Srihari NN, Sydenham M, Wells E, Witts S, Hall E; COSTAR Investigators.

Eur J Cancer. 2018 Nov;103:249-258. doi: 10.1016/j.ejca.2018.08.006. Epub 2018 Oct 1.


Non-invasive ventilation for a rapidly deteriorating palliative patient.

Green E, Stockton L, De Winton E.

BMJ Support Palliat Care. 2019 Jun;9(2):226-228. doi: 10.1136/bmjspcare-2018-001528. Epub 2018 Jun 6. No abstract available.


Non-Gestational Choriocarcinoma with Widespread Metastases Presenting with Type 1 Respiratory Failure in a 39-Year-Old Female: Case Report and Review of the Literature.

Stockton L, Green E, Kaur B, De Winton E.

Case Rep Oncol. 2018 Mar 14;11(1):151-158. doi: 10.1159/000486639. eCollection 2018 Jan-Apr.


Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.

Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N, Pepperell J, Howell T, Stewart SA, Penz E, Jordan N, Morley AJ, Zahan-Evans N, Smith S, Batchelor TJP, Marchbank A, Bishop L, Ionescu AA, Bayne M, Cooper S, Kerry A, Jenkins P, Toy E, Vigneswaran V, Gildersleve J, Ahmed M, McDonald F, Button M, Lewanski C, Comins C, Dakshinamoorthy M, Lee YCG, Rahman NM, Maskell NA.

Lancet Oncol. 2016 Aug;17(8):1094-1104. doi: 10.1016/S1470-2045(16)30095-X. Epub 2016 Jun 23.


The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.

Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Morley A, White P, Rahman NM, De Winton E, Clive A, Masani V, Arnold DT, Dangoor A, Guglani S, Jankowska P, Lowndes SA, Harvey JE, Braybrooke JP, Maskell NA.

Br J Cancer. 2015 Mar 31;112(7):1175-82. doi: 10.1038/bjc.2015.62.


The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.

Arnold DT, Hooper CE, Morley A, White P, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Rahman NM, De Winton E, Clive A, Masani V, Dangoor A, Guglani S, Jankowska P, Lowndes SA, Harvey JE, Braybrooke JP, Maskell NA.

Br J Cancer. 2015 Mar 31;112(7):1183-9. doi: 10.1038/bjc.2015.77.


Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases.

Clive AO, Wilson P, Taylor H, Morley AJ, de Winton E, Panakis N, Rahman N, Pepperell J, Howell T, Batchelor TJ, Jordan N, Lee YC, Dobson L, Maskell NA.

BMJ Open. 2015 Jan 9;5(1):e006673. doi: 10.1136/bmjopen-2014-006673.


Target localisation for tumour bed radiotherapy in early breast cancer.

Hansen CJ, de Winton E, Guglani S, Vamvakas E, Willis D, Chua BH.

J Med Imaging Radiat Oncol. 2012 Aug;56(4):452-7. doi: 10.1111/j.1754-9485.2012.02380.x.


Supplemental Content

Loading ...
Support Center